Bioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonist
50% Lesion clearance and regression of Herpes Zoster Neuralgia within 48 – 72 hours
BOSTON, MASSACHUSETTS, March 06, 2024 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, announced today the preprint in ResearchGate entitled “Association of Rapid Shingles Lesion Clearance and Regression of Herpes Zoster Neuralgia in Case Study Using Topical Galectin-3 Antagonism” showed a time lapsed clearance of the shingles lesions using a topical Galectin-3 antagonist. Vaccines have been developed to prevent shingles, but there are few effective antiviral therapies capable of treating the outbreak while reducing the pain associated with the condition. The case study demonstrated a rapid response in the reduction of pain the size of the lesion area, due to a galectin antagonist.
Herpes Zoster the pre-publication can be viewed at:
“There are preventive vaccines for shingles of variable efficacy, but the search for an efficacious therapeutic intervention, that terminates clinical progression of shingles, has so far proven elusive,” said Dr. Leslie Ajayi, Bioxytran Chief Medical Officer. “This case study constitutes a proof of concept of the benefit of using a galectin antagonist in human shingles infection. If research dollars are available, we would like to conduct an expanded clinical series, with a topical formulation of our galectin-3 antagonists in more in a varied patient pool consisting of 20 to 30 men and women. In parallel, we would like to examine the efficacy of an orally active galectin-3 antagonist compared to the topical preparation with the ultimate goal of a Randomized Controlled Trial compared against the standard of care (SOC). If our hypothesis is supported by clinical evidence, it may cause a paradigm shift and benefit, in the management of shingles and herpetic neuralgia. The subsequent possibilities are enormous, and would have an impact in the fields of virology, dermatology, and neuroscience.”
About Bioxytran, Inc.
Bioxytran, Inc. is a clinical stage biotechnology company pioneering a library of novel carbohydrate structures using artificial intelligence software that interprets the Nuclear Magnetic Resonance imaging of druggable targets like the galectin fold to create a rational drug design. The leading drug candidates vetted by in vitro testing, are capable of neutralizing viruses. The peer-reviewed discovery of the galectin fold located on the spike proteins of viruses such as COVID-19, RSV, and H1N1 demonstrate there exists a conserved region on the spike in which Bioxytran’s molecules achieve virus neutralization. The extent of the carbohydrate structure’s ability to neutralize untested viruses is unknown just like the initial discovery of antibiotics last century and its ability to treat a broad spectrum of bacterial infections. Applications of this platform technology extend to the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, Prolectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases. Bioxytran’s other development programs are for pulmonary fibrosis and stroke treatment. More information can be found at www.bioxytraninc.com
Investor Relations
Michael Sheikh
509-991-0245
Forward-Looking Statements
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.
